EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
04 Dezembro 2023 - 6:06PM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to improve the lives
of patients with serious retinal diseases, today announced that it
has commenced an underwritten public offering of $175 million of
shares of its common stock. All of the shares are being offered by
EyePoint. In addition, EyePoint intends to grant the underwriters
an option for a period of 30 days to purchase up to an additional
$26.25 million of shares of EyePoint’s common stock at the public
offering price, less the underwriting discount.
J.P. Morgan, TD Cowen and Guggenheim Securities
are acting as joint book running managers for the offering. The
offering is subject to market conditions and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
EyePoint intends to use the net proceeds that it
will receive from the offering to advance clinical development of
EYP-1901 for wet age related macular degeneration through the
initiation of and reporting of topline data from two pivotal Phase
3 clinical trials, as well as support its earlier stage pipeline
development initiatives, and for general corporate purposes.
The securities described above to be issued and
sold are being offered by the Company pursuant to a shelf
registration statement on Form S-3 (No. 333-275125) previously
filed with the Securities and Exchange Commission (SEC) on October
20, 2023 and declared effective by the SEC on October 30, 2023.
The securities will be offered by means of a
prospectus supplement and accompanying prospectus relating to the
offering that form a part of the applicable registration
statements. A preliminary prospectus supplement and the
accompanying prospectus relating to and describing the terms of the
offering will be filed with the SEC and will be available on the
SEC’s website at www.sec.gov. Copies of the preliminary prospectus
supplement, when available, and accompanying prospectus relating to
the offering may be obtained from J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or
Guggenheim Securities, LLC, Attention: Equity Syndicate Department,
330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone
at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
clinical-stage company committed to developing and commercializing
therapeutics to help improve the lives of patients with serious
retinal diseases. The Company's pipeline leverages its proprietary
bioerodible Durasert E™ technology for sustained intraocular drug
delivery. The company’s lead product candidate, EYP-1901, is an
investigational sustained delivery treatment for VEGF-mediated
retinal diseases combining vorolanib, a selective and
patent-protected tyrosine kinase inhibitor (TKI) with Durasert E™.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences
for the localized treatment of all ophthalmic diseases. Additional
pipeline programs include EYP-2301, a promising Tie-2 activator,
razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to
potentially improve outcomes in wet AMD and diabetic eye disease.
The proven Durasert® drug delivery platform has been safely
administered to over thousands of patient eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE
SECURITIES LITIGATION ACT OF 1995: To the extent any statements
made in this press release deal with information that is not
historical, these are forward-looking statements under the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements regarding the timing and success
of the proposed offering, as well as the anticipated use of
proceeds for the proposed offering and other statements identified
by words such as “will,” “potential,” “could,” “can,” “believe,”
“intends,” “continue,” “plans,” “expects,” “anticipates,”
“estimates,” “may,” other words of similar meaning or the use of
future dates. Forward-looking statements by their nature address
matters that are, to different degrees, uncertain. Uncertainties
and risks may cause EyePoint’s actual results to be materially
different than those expressed in or implied by EyePoint’s
forward-looking statements. For EyePoint, this includes
satisfaction of the customary closing conditions of the offering,
delays in obtaining required stock exchange or other regulatory
approvals, stock price volatility and uncertainties relating to the
financial markets, the medical community and the global economy,
and the impact of instability in general business and economic
conditions, including changes in inflation, interest rates and the
labor market. More detailed information on these and additional
factors that could affect EyePoint’s actual results are described
in EyePoint’s filings with the SEC, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2022, as
revised or supplemented by its Quarterly Reports on Form 10-Q and
other documents filed with the SEC. All forward-looking statements
in this news release speak only as of the date of this news
release. EyePoint undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investors:Christina TartagliaStern
IRDirect: 212-698-8700christina.tartaglia@sternir.com
Media ContactAmy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024